At the heart of global developments in health and wellness, Vitafoods Europe 2026 once again served as the meeting point for the leading players in the nutraceutical industry. Among them, the Tsetis Pharmaceutical Group of Companies (OFET), with its flagship companies UNI-PHARMA and InterMed, confirmed its leadership position, not only in Greece but also on the international stage, presenting solutions that bridge the gap between traditional pharmacology and modern longevity science.
The Longevity Strategy: Prevention Over Cure
By 2026, the concept of "longevity" has ceased to be a mere marketing buzzword and has evolved into a comprehensive scientific discipline. OFET, under the leadership of Julia Tsetis, recognized this shift early on. At Vitafoods Europe, the Group's presence was not limited to a simple product display but highlighted a new health paradigm: preventive care through specialized dietary supplements targeting cellular rejuvenation.
UNI-PHARMA and InterMed presented product lines leveraging the latest in biotechnology. From formulations enhancing cellular autophagy mechanisms to advanced probiotics and high-bioavailability vitamin supplements, OFET proved that the Greek pharmaceutical industry can lead in healthy aging research. This approach aligns with global trends where consumers seek scientifically proven solutions to maintain vitality over time.
Innovation with "Greek DNA" and Global Impact
One of the main points discussed during the Vitafoods panels was OFET's ability to transform local biodiversity into a global competitive advantage. Through Uni-Herbo, the Group utilizes Greek herbs and natural raw materials from Greek soil, applying strict pharmaceutical protocols to produce high-purity extracts.
- Extroversion: With a presence in over 70 countries, OFET acts as an ambassador for Greek entrepreneurship.
- R&D Investment: Over 10% of turnover is consistently invested in research and the development of new delivery forms.
- Sustainability: The green transition of the Group's factories serves as a model for the European industry, combining production with environmental respect.
Participation in Vitafoods Europe 2026 was not just a commercial move but a statement of power. In an era where Artificial Intelligence (AI) accelerates drug and molecule discovery, OFET integrates digital tools into its production process, ensuring that every product reaching the shelf is the result of thousands of simulations and exhaustive clinical trials.
The Future of Nutraceuticals and Social Responsibility
Julia Tsetis, President and CEO of the Group, has repeatedly emphasized that entrepreneurship must have a human face. This "Value for Man" philosophy was pervasive in the Group's presentation in Geneva. Developing nutraceuticals that are accessible and effective is not just about profits but about improving the quality of life for the general population.
"Innovation is meaningless if it does not translate into societal well-being. At OFET, we invest in science to add years to life, but more importantly, life to years," was a key message shared during meetings with international delegations.
In conclusion, Vitafoods Europe 2026 highlighted that the Greek pharmaceutical industry, led by OFET, has managed to shed the introversion of the past. Armed with quality, scientific excellence, and a vision for a healthier planet, UNI-PHARMA and InterMed are laying the foundations for the next decade of the global health market, where prevention and longevity will be at the core of human activity.
